


PT Medikaloka Hermina Tbk 1Q 2020 Presentation

May 2020

Hermina – Our Team







1. Company Overview

AN ANAK IA bekasi

Introduction to Hermina

Hermina is one of the largest hospital groups in Indonesia with more than 35 years of experience in women and children care and a differentiated business model. Hermina is uniquely positioned to take advantage of low healthcare penetration and universal health coverage roll-out through the Jaminan Kesehatan Nasional ("JKN") scheme in Indonesia.

Unique Business Model

- One of the Largest Private Hospital Groups
 - 37 hospitals and 4,409 beds as of March 31, 2020
 - **General hospital** providing a wide range service offerings, with a strong heritage in women and children care
- 'Doctor Partnership' Model
 - Top specialist doctors own a minority stake at each hospital
 - (i) Helps to attract and retain quality doctors, and (ii) supports growth plan going forward
- Patient Segment Positioning Fast growing middle class and rising affluence
 - Strength in women and children care provides a good entry point for Indonesians of productive age
- Early Mover Advantage in JKN Visits driven by JKN, as well as private pay, insurance, and corporate patients
- Proven Track Record Successfully developing new hospitals and optimizing capacity while maintaining profitability
- Alignment of Interest Doctor Partners + selfowned properties¹ + fully committed founders and credible institutional investors



Key Statistics (FY19)



Annual Out-Patient Visits

6.1M+

Annual In-Patient Admissions







100%

~3,800

Doctors and

Specialists

~55,000


Annual Babies Delivered

JKN Participation Across Hospitals



Service Offering Overview

Hermina hospitals are a network of general hospitals with a significant strength and wide offering in women and children care







1. As of March 31, 2020

2. Based on Frost & Sullivan's analysis that within the top private multi-specialty hospital chains, Hermina has the broadest offerings in women & children segment

Corporate History



Evolution on Number of Hospitals





Our Nationwide Hospital Network

Our Nationwide Hospital Network						
Type B Hospitals		Type C Hospitals				
Jatinegara	Kemayoran	 Pandanaran Tangkubanprahu Serpong Sukabumi Tangerang Arcamanik Galaxy Palembang Mekarsari Serpong Banyumanik Banyumanik Banyumanik Banyumanik Banyumanik Banyumanik Banyumanik Podomoro Pekalongan Medan Medan Pekanbaru Kendari Wonogiri¹ Karawang Jakabaring Padang 				
		Ciputat Makassar Lampung				
		Total Hospitals				
Bekasi	Depok	37 Hospitals ²				
		across 25 Cities in				
Daan Mogot	Bogor	1				
Grand Wisata	Pasteur	₽ ⁸ ^H 4&				



1. Conversion of acquired hospital is in progress


2. Excluding Provida Hospital in Jayapura which is owned by a local Papua organization but managed and operated by Hermina



2. Financial Update


A BEKASI

Resilient Revenue and EBITDA Performance Despite Pandemic



Gross Profit & Gross Margin (IDR billions, %)








1. EBITDA is calculated by operating income + depreciation and amortization + adjustment for non-operating items (loss on disposal of fixed asset, gain on sale of fixed asset, and other income (expense)) and adjustment for non-cash items (allowance for impairment losses and post-employment benefit expense).


Key Balance Sheet Items – Working Capital Turnover Days




Inventory Days² (Days)








Cash Conversion Cycle Days (Days)



Net Working Capital

(IDR billions)






1. Trade receivable days are calculated based on the average of beginning and ending balance of trade receivables over the period of last 12 months (LTM) divided by LTM Sales.

2. Calculated based on the average of beginning and ending balance of LTM period divided by LTM COGS.

*) The other account payable to related parties is included

Stable Growth in Both Private and JKN Patients




Inpatient Days by Payor Type



Outpatient Visit



Outpatient Visits by Payor Type





Consistent Improvement in EBITDA Margin


(IDR billions)	1Q19	1Q20
Revenue	901.5	983.9
EBIT	138.8	169.2
% Margin	15.4%	17.2%
+ Depreciation and Amortization (D&A)	50.8	59.9
Adjustment for back non-cash items ¹		
+ Post-employment benefits	9.4	10.3
+ Allowance for impairment losses	21.8	10.2
Adjustment for non-operational income / (expense)		
+ Loss on disposal of fixed asset	(0.2)	(0.2)
- Gain on sale fixed asset	(0.2)	(0.0)
- Other income / (expense) ²	0.0	3.4
+ IPO related expenses	-	-
EBITDA (EBIT + D&A + Adjustments)	220.7	246.0
% Margin	24.5%	25.0%



1. Methodology is consistent with the EBITDA calculation methodology of the peer group of Siloam and Mitra Keluarga

2. Other income and expenses include items that are non-operational in nature such as sponsorship income, seminar income, patient overpayment, CSR and charitable donation expenses, and other miscellaneous income and expenses. Other income and expenses exclude the minority shares subscription income (IDR 706mn in 1Q19 and IDR 2,661mn in 1Q20)


Healthy Balance Sheet With 0.5x Net Debt-to-EBITDA





Debt is calculated by short-term bank loans + current portion of long-term liabilities + medium term notes + long-term liabilities net of current portion: bank loans + mandatory convertible notes + finance lease payables and consumer finance


Consistent Positive Cash Flow From Operations to Partly Fund Capex




Cash Flow from Operations

Cash Flow from Investing Activities

Cash Flow from Financing Activities



(IDR billions, %)





Attractive Share Valuation With Improving ROIC

Share Price and LTM EV/EBITDA Multiple (IDR) 4,500 Executed price of shares purchased 21.0 (x) by the Management 4,000 19.0 3,500 17.0 15.0 3,000 13.0 2,500 11.0 2.000 9.0 1.500 7.0 17/05/18 17/08/18 17/11/18 17102/19 17/05/19 17_{108/19} 17/17/19 17102120 17105/20 Share Price (LHS) LTM EV/EBITDA Multiple (RHS)


Track Record of Returning Capital to Investors

Dividend

- Dividend for FY2018: IDR 11 per share
- Dividend for FY2019: IDR 12 per share

Shares Buyback

- Hermina is currently conducting a buyback program
- Nominal value of shares to be bought back is IDR 100bn at maximum for as many as 30 million shares
- Partial buyback has been realized




1. Return on Invested Capital (ROIC) is calculated based on EBIT, tax rate of 25%, and average balance of invested capital.



3. Hospital Development

A BEKASI


Hospitals Under Development



Hermina Kutabumi











Investor Relations Contact and Coverage

Investor Relations Contact: ir@herminahospitals.com

Upcoming Events:

- Credit Suisse 2020 Asia Healthcare Virtual Conference (June 10th 12th, 2020)
- J.P. Morgan Indonesia Virtual Healthcare Day (June 11th, 2020)

Analyst Coverage:

Analyst	Share Price Target (IDR)	Rating
Rachel Christabelle Sual	4,700	Buy
Edi Chandren	4,500	Buy
Patricia Gabriela	3,200	Add
Steven Ho	3,700	Outperform
Maynard Priajaya Arif	3,700	Buy
Laura Oei	4,100	Buy
Ari Jahja	3,810	Outperform
Lakshmi Rowter	5,200	Buy
Jessica Pratiwi	4,800	Buy
	Rachel Christabelle Sual Edi Chandren Patricia Gabriela Steven Ho Maynard Priajaya Arif Laura Oei Ari Jahja Lakshmi Rowter	Rachel Christabelle Sual4,700Edi Chandren4,500Patricia Gabriela3,200Steven Ho3,700Maynard Priajaya Arif3,700Laura Oei4,100Ari Jahja3,810Lakshmi Rowter5,200





PT Medikaloka Hermina Tbk

BEKASI

www.herminahospitals.com